S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018

Hybridtumor eines Riesenzellfibroblastoms und eines Dermatofibrosarcoma protuberans

Wir berichten über ein zum Zeitpunkt der Erstmanifestation 10 Monate altes Kind mit einem Hybridtumor aus Riesenzellfibroblastom (RZFB) und Dermatofibrosarkoma protuberans (DFSP). Das RZFB ist ein seltener Tumor, der mit dem DFSP die Translokation (t17;22) (q22;13) und immunphänotypische Eigenschaften teilt und daher von seinen Erstbeschreibern als kindliche Form des DFSP eingeordnet wurde. Das RZFB hat mit einer Kombination aus Spindelzellproliferaten, häufig hypozellulären Arealen mit kollagenfaserreichem oder myxoidem Stroma, sinusoid-artigen pseudovaskulären Aufweitungen zwischen den Kollagenfasern, die von multinukleären Riesenzellen umsäumt werden, jedoch ein ihm eigenes histologisches Bild. Das RZFB, das sich klinisch als langsam wachsende, i.d.R. schmerzlose Schwellung manifestiert, tritt präferentiell im Kindesalter auf. Das mittlere Erkrankungsalter liegt bei 6 Jahren. Die Therapie der Wahl ist die Exzision mit einem ausreichenden Sicherheitsabstand. Unsere junge Patientin zeigt ein Jahr nach Exzision mit 2 cm Sicherheitsabstand einen rezidivfreien Verlauf.

Role of a new acellular dermal matrix in a multistep combined treatment of dermatofibrosarcoma protuberans of the lumbar region: a case report

Background

Dermatofibrosarcoma protuberans (DFSP) is a rare skin fibroblastic tumor, with a high rate of recurrence. The treatment of DFSP is generally surgical, and wide local excision is the mainstay of surgical treatment. Therefore, complete assessment of all surgical margins is fundamental before definitive reconstruction. The reconstruction is a challenge for plastic surgeons, especially in particular anatomical areas (for aesthetic or functional problems) or in patients who are not candidates for more complex surgical treatments. We describe an alternative approach for reconstructive treatment of the lumbar area after wide excision of DFSP (without fresh-frozen sections) in a young obese woman with a history of smoking, using a new type of acellular dermal matrix (ADM) in a combined management protocol. The benefits of ADM are numerous: immediate wound closure and prevention of infections and excessive drying; minimal donor site morbidity; and good functional and aesthetic outcomes. Moreover, it is a temporary cover while the anatomical specimen is histologically analyzed, without donor site morbidity or prevention of any future surgery (if the margins are not tumor-free) or radiotherapy.

Case presentation

In October 2019, a 34-year old obese Caucasian Woman with a history of smoking came to our institute for a multinodular growing polypoid mass in her lumbar region. An incisional biopsy diagnosed DFSP. The patient underwent proper staging. A wide local excision with 3 cm clinically healthy tissue margins down to the muscle fascia was performed and the defect was repaired using a combined approach with a new artificial bilaminar dermal template (Pelnac®, Gunze Ltd., Osaka, Japan) and a negative-pressure wound therapy system (V.A.C.®, KCI, San Antonio, USA). After the final histological examination revealed tumor-free margins, a split-thickness graft was harvested from the right gluteus and fixed to the new derma with negative-pressure wound therapy. Postoperative radiotherapy was not necessary. After 15 days, the wound had healed without complications, with satisfactory aesthetic outcome and with no limitation of back motion or pain. After 6 months of follow-up, the patient was free from disease.

Conclusions

This is the first reported case of Pelnac® use in DFSP reconstruction of the lumbar region. We believe that the multistep approach described herein may be a good alternative approach in selected patients with wide resections in particular anatomical areas, especially when frozen sections (with Mohs micrographic surgery) are not available.

Current Approaches for Personalized Therapy of Soft Tissue Sarcomas

Soft tissue sarcomas (STS) are a highly heterogeneous group of cancers of mesenchymal origin with diverse morphologies and clinical behaviors. While surgical resection is the standard treatment for primary STS, advanced and metastatic STS patients are not eligible for surgery. Systemic treatments, including standard chemotherapy and newer chemical agents, still play the most relevant role in the management of the disease. Discovery of specific genetic alterations in distinct STS subtypes allowed better understanding of mechanisms driving their pathogenesis and treatment optimization. This review focuses on the available targeted drugs or drug combinations based on genetic aberration involved in STS development including chromosomal translocations, oncogenic mutations, gene amplifications, and their perspectives in STS treatment. Furthermore, in this review, we discuss the possible use of chemotherapy sensitivity and resistance assays (CSRA) for the adjustment of treatment for individual patients. In summary, current trends in personalized management of advanced and metastatic STS are based on combination of both genetic testing and CSRA.